Skip to content
Education
Isle of NAM
High-Throughput Screening

High-Throughput Screening

Table of Contents

Definition

High-throughput screening (HTS) is the automated, parallel testing of very large libraries of chemical compounds, or of genomic and RNA-interference reagents, against a defined biological target or a phenotypic cell system, with the objective of identifying active modulators, termed hits.1 It models the interaction of small molecules with purified molecular targets, such as enzymes, receptors, and ion channels, in biochemical assay formats, or with integrated cellular pathways in engineered and native cell-based assays whose activity depends upon the target under investigation.1 Increasingly, HTS is also applied to identify chemical probes of gene, pathway, and cell functions, extending its scope from pharmaceutical hit discovery into systematic chemical genomics.2

Structurally, an HTS campaign executes miniaturized assays in microplate formats of increasing density, including 96-, 384-, and 1,536-well plates, in which robotic liquid-handling systems dispense reagents at microlitre to nanolitre scale and automated plate readers record fluorescence, luminescence, or absorbance signals as quantitative readouts.1 2 Assay volumes and reagent concentrations are deliberately minimized to contain cost at the scale of hundreds of thousands of individual tests, and the entire workflow, from compound management through detection to data capture, is orchestrated by laboratory automation and analysis software.1 2

Purpose

The primary value proposition of HTS is that it permits the exhaustive, unbiased interrogation of an entire compound library without any prior knowledge of the chemotype likely to act at the target, thereby enabling the discovery of novel chemical starting points that rational, knowledge-based approaches cannot anticipate.1 By parallelizing and automating what was historically a serial, manual pharmacological process, HTS reduces the time and cost per tested compound by orders of magnitude and has become a mainstay of pharmaceutical development.2

HTS also constitutes a foundational new approach methodology (NAM) because its cell-based and biochemical assays are conducted in human-relevant in vitro systems before any animal experimentation is contemplated. Large federal programmes, most prominently the United States Tox21 collaboration, apply HTS to thousands of environmental and industrial chemicals with the explicit aims of modernizing human hazard characterization, prioritizing chemicals for further testing, and reducing and ultimately replacing animal use in toxicology.3

Methodology

The construction of an HTS campaign begins with the design of the screening collection, which may be a large diversity library screened in its entirety or a focused, knowledge-based subset selected for presumed activity at the target.1 Screening assays for hit discovery are typically conducted at compound concentrations of 1 to 10 micromolar, and assay tolerance to the solvent dimethyl sulfoxide is established at concentrations of up to 10 percent.1

Assay development proceeds through systematic optimization of reagents, signal detection, and protocol miniaturization, followed by validation in pilot screens.1 Quality is judged against the Z-prime factor, a statistical parameter that combines the assay signal window with the variance around both high and low control signals and that has become the industry standard for assessing assay suitability.1 Pilot studies additionally quantify the false-positive and false-negative rates of the assay, and reconfiguration is undertaken when either is unacceptably high.1 Because primary hits may act at unintended sites of action, confirmed activity requires secondary and orthogonal assays before a hit is advanced.1

At the platform level, quantitative HTS (qHTS) refines the classical single-concentration design by screening every compound as a titration series, using at least seven five-fold serial dilutions spanning approximately four orders of magnitude in 1,536-well plate format, so that each library member yields a full concentration-response profile and a curve-class assignment that distinguishes genuine activity from artifacts.2

Performance

Empirically, qHTS has demonstrated the capacity to generate concentration-response profiles for chemical libraries exceeding one hundred thousand compounds, providing potencies and efficacy estimates for every library member rather than a binary active-or-inactive call.2 In validated assay campaigns, observed hit rates are low by design: in an illustrative luminescence-based reporter assay, agonist-mode hit rates were typically below 0.5 percent of screened compounds, and antagonist-mode rates approximately 2 to 3 percent, with correspondingly low false-positive and false-negative frequencies.1

Reproducibility is quantified through statistical control of plate-level and assay-level variation. Because potency estimates for a single compound can vary considerably across replicate concentration-response profiles within a qHTS experiment, automated quality-control procedures based on analysis of variance have been developed to identify and filter inconsistent profiles, accounting for experimental factors that otherwise degrade reliability and reproducibility.4

Current technical boundaries include assay interference and compound aggregation, which generate false positives that only orthogonal confirmation can eliminate.1 2 In addition, conventional two-dimensional monolayer cultures impose physiological constraints on cell-based screens, which three-dimensional organoid systems are progressively addressing at the cost of greater culture and analysis complexity.5

Applications

Primary applications of HTS include hit identification in pharmaceutical lead discovery and the systematic discovery of chemical probes for basic biological research.1 2 In industrial toxicology and regulatory science, standardized HTS platforms underpin the Tox21 collaboration of United States federal partners, including the National Institute of Environmental Health Sciences and National Toxicology Program, the Environmental Protection Agency, and the National Center for Advancing Translational Sciences, which screens a shared library of approximately ten thousand environmental and industrial chemicals across cell-based assays to characterize pathway-level hazards relevant to human exposure.3

HTS is a mature, fully deployed technology in the pharmaceutical and biotechnology industries and in academic screening centres, and it is an established instrument of public-sector chemical genomics.2 3 Its deployment stage is therefore industrial and regulatory, with platform-level refinements, notably organoid-based and high-content formats, now moving from methodological development toward routine readiness.5

Variations

  • High-Content Screening extends HTS from single endpoint readouts to automated microscopy and multiparametric image analysis, quantifying rich cellular phenotypes at single-cell resolution; modern phenotypic drug discovery couples this capacity with contemporary tools to identify compounds that modulate disease-relevant phenotypes without prior target knowledge.6
  • Label-Free Screening replaces fluorescent and radiolabelled reporters with optical, electrical, and mass-spectrometric detection of native cellular and molecular responses, avoiding label-associated artifacts while expanding the range of targets compatible with screening.7
  • Droplet-Based Microfluidic Screening miniaturizes each assay into monodisperse picolitre droplets generated, manipulated, and sorted on microfluidic chips at kilohertz rates, achieving ultrahigh throughput with minimal reagent consumption.8
  • Organoid-Based Screening adapts HTS to three-dimensional, patient-derived organoid cultures, whose culturing systems and analysis tools increasingly make organoids accessible to high-throughput and high-content formats with machine-learning support.5
  • Fragment-Based Screening screens small libraries of low-molecular-weight fragments, generally of twenty or fewer heavy atoms, whose weak but efficient binding is detected by biophysical methods; it is established as a complementary approach to classical HTS.9
  • Virtual Screening performs the selection of candidate molecules in silico, automatically evaluating large databases of molecular structures against a target or a known ligand, with machine-learning and deep-learning methods increasingly accelerating the triage of ultra-large libraries prior to experimental testing.10

  1. Hughes JP, Rees S, Kalindjian SB, Philpott KL, Principles of early drug discovery, British Journal of Pharmacology, 2011-03.
    This review outlines the early stages of the drug discovery pipeline, including high-throughput screening, assay validation, and hit triage, and describes the Z-prime factor and the role of library-scale screening in identifying novel chemical starting points for lead discovery. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  2. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP, Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries, Proceedings of the National Academy of Sciences, 2006-08-01.
    This study introduces quantitative HTS, in which every compound is screened as a multi-point titration series in 1,536-well plates, and demonstrates accurate concentration-response profiling of libraries exceeding one hundred thousand compounds while reducing false positives through curve classification. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  3. Tice RR, Austin CP, Kavlock RJ, Bucher JR, Improving the Human Hazard Characterization of Chemicals: A Tox21 Update, Environmental Health Perspectives, 2013-07.
    This report describes the United States federal Tox21 collaboration, in which partner agencies apply automated, cell-based high-throughput screening to a shared library of approximately ten thousand chemicals in order to modernize human hazard characterization and reduce animal use in toxicology. ↩︎ ↩︎ ↩︎

  4. Shockley KR, Gupta S, Harris SF, Lahiri SN, Peddada SD, Quality Control of Quantitative High Throughput Screening Data, Frontiers in Genetics, 2019-04.
    This article analyses the variability of potency estimates across replicate concentration-response profiles in qHTS experiments and introduces an automated, analysis-of-variance-based quality-control procedure for identifying and filtering inconsistent screening results. ↩︎

  5. Lampart FL, Iber D, Doumpas N, Organoids in high-throughput and high-content screenings, Frontiers in Chemical Engineering, 2023-03-21.
    This review discusses developments in organoid culturing systems and analysis tools that make three-dimensional organoids accessible to high-throughput and high-content screening, and summarizes the potential of machine learning and computational modelling in conjunction with organoid-based assays. ↩︎ ↩︎ ↩︎

  6. Vincent F, Nueda A, Lee J, et al., Phenotypic drug discovery: recent successes, lessons learned and new directions, Nature Reviews Drug Discovery, 2022-05-30.
    This review traces the re-emergence of phenotypic drug discovery over the past decade, describing how modern phenotypic approaches combine therapeutic-effect-based screening with contemporary cellular and imaging tools to deliver first-in-class medicines. ↩︎

  7. Fang Y, Label-free drug discovery, Frontiers in Pharmacology, 2014-03-27.
    This review examines label-free detection technologies for drug discovery, contrasting them with label-dependent molecular assays and discussing their capacity to measure native cellular and molecular responses without reporter-associated artifacts. ↩︎

  8. Vladisavljević GT, Droplet Microfluidics for High-Throughput Screening and Directed Evolution of Biomolecules, Micromachines, 2024-07-29.
    This review explains how droplet microfluidic chips generate, manipulate, and sort monodisperse droplets at kilohertz rates, enabling highly automated and miniaturized high-throughput screening for the directed evolution of proteins and nucleic acids. ↩︎

  9. Bon M, Bilsland A, Bower J, McAulay K, Fragment-based drug discovery—the importance of high-quality molecule libraries, Molecular Oncology, 2022-06-24.
    This review describes fragment-based drug discovery as a complementary approach to high-throughput screening, in which small libraries of low-molecular-weight fragments are screened with biophysical methods, and argues that library quality is the principal determinant of success. ↩︎

  10. Oliveira TAd, Silva MPd, Maia EHB, Silva AMd, Taranto AG, Virtual Screening Algorithms in Drug Discovery: A Review Focused on Machine and Deep Learning Methods, Drugs and Drug Candidates, 2023-05-05.
    This review surveys computational virtual screening algorithms, including ligand-based and structure-based approaches, and describes how machine-learning and deep-learning methods accelerate the evaluation of large compound databases in early drug discovery. ↩︎